Vitrimark, Inc.
| Location: | MA, US | | Speaker: | Arijit Bose | | Title: | Dr. | | Primary Industry: | Pharma & Biotech | | Executive Summary: | Vitrimark, Inc. exploits the unique advantages provided by nanoscale cryoimaging of biofluids to identify ultrastructural biomarkers for utility and integration in the drug development process. Current methods for determining biomarkers involve functional assays. The fundamental premise in Vitrimark, Inc.’s technology is that ultrastructural changes precede functional changes and thus allow earlier detection potential. Morphology changes at nanoscale resolution will be correlated to functional and phenotypic changes. This approach alleviates biochemical assays that probe functional alterations in genes and proteins, and require a priori knowledge of specific target genes. Vitrimark\'s initial target is structural biomarkers for prostate cancer; it will then target prediabetes and diabetes. | | Venture is: | Seed Level |
|
|
|